CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (292)	11/15/1999 11:52:00 PM
From: Bob L	Read Replies (1) of 666

According to a Piper Jaffry report, at the recent Chemotherapy Foundation Symposium in New York, some preliminary results of the bexxar/fludarabine study were presented. All evaluable patients (there were 40 in the study) have responded to the combination. Importantly, no HAMA (human anti-mouse antibody) responses were observed. Proving once again that Vector1 has a nose for the news on this topic. Unfortunately, SmithKline announced in a conference call last month that refiling of the BLA will be end of first quarter 2000, which I don't think has been posted here before. Anyone hear this call?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next